[go: up one dir, main page]

BRPI0412909A - uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer - Google Patents

uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer

Info

Publication number
BRPI0412909A
BRPI0412909A BRPI0412909-1A BRPI0412909A BRPI0412909A BR PI0412909 A BRPI0412909 A BR PI0412909A BR PI0412909 A BRPI0412909 A BR PI0412909A BR PI0412909 A BRPI0412909 A BR PI0412909A
Authority
BR
Brazil
Prior art keywords
manufacture
parp activity
inhibiting parp
cancer medicine
rnai
Prior art date
Application number
BRPI0412909-1A
Other languages
English (en)
Inventor
Thomas Helleday
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412909(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Sheffield filed Critical Univ Sheffield
Publication of BRPI0412909A publication Critical patent/BRPI0412909A/pt
Publication of BRPI0412909B1 publication Critical patent/BRPI0412909B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)

Abstract

"USO DE RNAI INIBINDO ATIVIDADE DE PARP PARA A FABRICAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE CáNCER". A presente invenção se refere ao uso de um agente que inibe a atividade de uma enzima que media reparo de uma quebra do filamento do DNA na fabricação de um medicamento para o tratamento de doenças causadas por um defeito em um gene que media a recombinação homóloga.
BRPI0412909-1A 2003-07-25 2004-07-23 Uso de um inibidor de poli (adp-ribose) polimerase 1 (parp-1) para a fabricação de um medicamento para o tratamento de células de câncer defeituosas em recombinação homóloga BRPI0412909B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0317466.1 2003-07-25
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
PCT/GB2004/003235 WO2005012524A1 (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer

Publications (2)

Publication Number Publication Date
BRPI0412909A true BRPI0412909A (pt) 2006-09-26
BRPI0412909B1 BRPI0412909B1 (pt) 2022-04-12

Family

ID=27772701

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412909-1A BRPI0412909B1 (pt) 2003-07-25 2004-07-23 Uso de um inibidor de poli (adp-ribose) polimerase 1 (parp-1) para a fabricação de um medicamento para o tratamento de células de câncer defeituosas em recombinação homóloga

Country Status (18)

Country Link
US (5) US8859562B2 (pt)
EP (1) EP1649017B2 (pt)
JP (3) JP5519097B2 (pt)
KR (1) KR101136702B1 (pt)
CN (3) CN102935230B (pt)
AT (1) ATE516353T1 (pt)
AU (1) AU2004261779B2 (pt)
BR (1) BRPI0412909B1 (pt)
CA (1) CA2533423C (pt)
DK (1) DK1649017T4 (pt)
ES (1) ES2367433T5 (pt)
GB (2) GB0317466D0 (pt)
NO (1) NO338398B1 (pt)
NZ (1) NZ545307A (pt)
PL (1) PL1649017T5 (pt)
PT (1) PT1649017E (pt)
WO (1) WO2005012524A1 (pt)
ZA (1) ZA200601386B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
PT1660095E (pt) 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
AU2004294790B2 (en) 2003-12-01 2010-03-11 Kudos Pharmaceuticals Limited DNA damage repair inhibitors for treatment of cancer
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
BRPI0606191A2 (pt) 2005-02-25 2009-06-09 Inotek Pharmaceuticals Corp compostos de amino e carboxamido tetracìclicos e métodos do seu uso
CA2620052A1 (en) 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
EP1962843B1 (en) * 2005-11-25 2011-02-23 Pharma Mar S.A., Sociedad Unipersonal Use of parp-1 inhibitors
EP2092083A2 (en) 2006-10-20 2009-08-26 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer
CN101674820B (zh) * 2006-12-26 2013-09-25 药品循环公司 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标志物的方法
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
GB0707556D0 (en) * 2007-04-19 2007-05-30 Isis Innovation Treatment for cancer
JP5335673B2 (ja) 2007-06-20 2013-11-06 学校法人 埼玉医科大学 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
WO2009027650A1 (en) * 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
US8236802B2 (en) 2007-10-03 2012-08-07 Eisai Inc. PARP inhibitor compounds, compositions and methods of use
WO2009113579A1 (ja) 2008-03-11 2009-09-17 学校法人埼玉医科大学 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
AU2009308423B2 (en) * 2008-10-24 2013-08-29 Magnachem International Laboratories, Inc. Method for screening for compounds selectively interacting with Rad9
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
AU2011293635B2 (en) 2010-08-24 2015-11-26 Children's Medical Center Corporation Methods for predicting anti-cancer response
US20140315973A1 (en) * 2010-10-07 2014-10-23 Agency For Science, Technology And Research Parp-1 inhibitors
CN103826623A (zh) 2011-07-22 2014-05-28 厄尔莱克斯制药公司 合成致死与癌症的治疗
DK3415915T3 (da) * 2012-02-23 2024-11-04 Childrens Medical Center Fremgangsmåde til at forudsige respons til PARP-inhibitorer
AU2013288265B2 (en) 2012-07-09 2017-04-06 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
WO2014172458A1 (en) * 2013-04-16 2014-10-23 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
EP3543353A1 (en) * 2013-09-23 2019-09-25 The University of Chicago Methods and compositions relating to cancer therapy with dna damaging agents
DK3102680T3 (en) 2014-02-07 2019-04-08 Vib Vzw INHIBITION OF NEAT1 FOR TREATMENT OF SOLID TUMORS
US9889141B2 (en) 2014-10-14 2018-02-13 Institute For Cancer Research Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer
SG10201909173PA (en) 2015-04-01 2019-11-28 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2017011907A1 (en) 2015-07-17 2017-01-26 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
CA3000275A1 (en) 2015-10-02 2017-04-06 University Of Copenhagen Small molecules blocking histone reader domains
DK3653709T3 (da) 2016-02-22 2021-03-08 Caribou Biosciences Inc Fremgangsmåder til modulering af dna-reparationsresultater
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
TWI793094B (zh) 2017-01-09 2023-02-21 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法
CN107058233A (zh) * 2017-05-03 2017-08-18 上海长海医院 一种减小肿瘤细胞对抗肿瘤药物的耐药性的方法
CN108048465A (zh) * 2017-12-20 2018-05-18 李风玲 一种抑制PARP基因用于治疗乳腺癌的siRNA
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
CN111989137A (zh) 2018-01-05 2020-11-24 赛博克萨1公司 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法
CR20210281A (es) 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
PH12021552205A1 (en) * 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
WO2021133886A1 (en) 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
JP7803876B2 (ja) 2020-04-28 2026-01-21 ライゼン ファーマシューティカルズ アーゲー ポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤として有用な新規化合物
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN114836472A (zh) * 2021-02-01 2022-08-02 中国人民解放军军事科学院军事医学研究院 PARP-1shRNA重组慢病毒载体、该载体稳定转染HaCaT的细胞系及其应用
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
MA63136A1 (fr) 2021-05-18 2024-06-28 Onconic Therapeutics Inc. Agent thérapeutique contre le cancer résistant à un inhibiteur de parp
US20250019708A1 (en) * 2021-11-19 2025-01-16 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
AU2023279251A1 (en) 2022-06-01 2024-12-05 Glaxosmithkline Intellectual Property (No. 4) Ltd. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024194401A1 (en) * 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en) * 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025183523A1 (ko) * 2024-02-29 2025-09-04 아주대학교 산학협력단 Parp 억제제 감수성 증가 방법
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5098861A (en) 1991-01-08 1992-03-24 Unitrode Corporation Method of processing a semiconductor substrate including silicide bonding
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AU8784698A (en) * 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
KR100632079B1 (ko) 1999-01-11 2006-10-04 아구론 파마슈티컬스, 인크. 폴리(ａｄｐ-리보오스) 중합 효소의 트리사이클릭 저해제
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
CA2412368A1 (fr) 2000-08-08 2002-02-14 Sanofi-Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
KR100804564B1 (ko) 2000-10-30 2008-02-20 쿠도스 파마슈티칼스 리미티드 프탈라지논 유도체
CA2444531A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
US7072771B2 (en) * 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
US7988693B2 (en) 2002-07-19 2011-08-02 Warsaw Orthopedic, Inc. Chisels and procedure for insertion of spinal implant in a spinal disc space
JP4027406B2 (ja) * 2003-03-12 2007-12-26 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
US7176188B2 (en) * 2003-05-07 2007-02-13 UniversitéLaval Method of lethally sensitizing human and animal cells
PT1660095E (pt) * 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
AU2004294790B2 (en) * 2003-12-01 2010-03-11 Kudos Pharmaceuticals Limited DNA damage repair inhibitors for treatment of cancer

Also Published As

Publication number Publication date
JP2006528618A (ja) 2006-12-21
CA2533423A1 (en) 2005-02-10
JP2014001210A (ja) 2014-01-09
PT1649017E (pt) 2011-09-30
PL1649017T5 (pl) 2015-02-27
EP1649017A1 (en) 2006-04-26
CN1856313B (zh) 2011-01-12
US20220062286A1 (en) 2022-03-03
PL1649017T3 (pl) 2011-12-30
CA2533423C (en) 2014-07-22
CN1856313A (zh) 2006-11-01
US20180000822A1 (en) 2018-01-04
ZA200601386B (en) 2007-04-25
DK1649017T3 (da) 2011-10-17
US20200237762A1 (en) 2020-07-30
CN102935230B (zh) 2016-08-10
NO20060906L (no) 2006-04-25
AU2004261779A1 (en) 2005-02-10
US20150005327A1 (en) 2015-01-01
CN102935230A (zh) 2013-02-20
DK1649017T4 (da) 2014-12-01
KR20060052877A (ko) 2006-05-19
GB0317466D0 (en) 2003-08-27
US20070179160A1 (en) 2007-08-02
EP1649017B1 (en) 2011-07-13
NZ545307A (en) 2009-08-28
CN1856572A (zh) 2006-11-01
JP2012102099A (ja) 2012-05-31
ES2367433T3 (es) 2011-11-03
AU2004261779B2 (en) 2008-07-24
CN1856572B (zh) 2013-11-06
KR101136702B1 (ko) 2012-04-20
WO2005012524A1 (en) 2005-02-10
JP5519097B2 (ja) 2014-06-11
EP1649017B2 (en) 2014-08-27
NO338398B1 (no) 2016-08-15
ATE516353T1 (de) 2011-07-15
GB0603874D0 (en) 2006-04-05
ES2367433T5 (es) 2014-11-03
GB2419882B (en) 2008-04-09
HK1094006A1 (en) 2007-03-16
JP5547164B2 (ja) 2014-07-09
GB2419882A (en) 2006-05-10
BRPI0412909B1 (pt) 2022-04-12
US8859562B2 (en) 2014-10-14
JP5848728B2 (ja) 2016-01-27
HK1182016A1 (zh) 2013-11-22

Similar Documents

Publication Publication Date Title
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
ECSP11010971A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un fármaco oral o no oral antidiabético
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
SG161267A1 (en) Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
CL2008001966A1 (es) Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques.
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
NZ623123A (en) A process for concentration of a polypeptide
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
BRPI0916885B8 (pt) composição farmacêutica
PL1889920T3 (pl) Sposób identyfikacji związków do terapii antynowotworowej in vitro
BR112021016907A2 (pt) Oligonucleotídeos de interferência com proteína de retardo mental do x frágil e métodos de sua utilização
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
MX2021010631A (es) Agentes de iarn modificados.
BRPI0601884A (pt) composição farmacêutica aplicável na terapêutica da doença de peyronie e respectivo processo de obtenção

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2841 DE 17/06/2025 POR TER SIDO INDEVIDA.